Intraperitoneal docetaxel combined with S-1 for advanced gastric cancer with peritoneal dissemination

Journal of Surgical Oncology

Volumn 105, Issue 1, 2012, Pages 38-42

  Fujiwara, Yoshiyuki ^a   Takiguchi, Shuji ^a   Nakajima, Kiyokazu ^a   Miyata, Hiroshi ^a   Yamasaki, Makoto ^a   Kurokawa, Yukinori ^a   Mori, Masaki ^a   Doki, Yuichiro ^a  

^a OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

Docetaxel; Gastric cancer; Intra peritoneal chemotherapy; Neoadjuvant chemotherapy; Peritoneal lavage cytology; S 1

Indexed keywords

DOCETAXEL; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ABDOMINAL ABSCESS; ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CARCINOMATOUS PERITONITIS; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CREATININE BLOOD LEVEL; CYTOLOGY; DIARRHEA; DRUG ERUPTION; DRUG FEVER; FATIGUE; FEMALE; GASTRECTOMY; HUMAN; INTESTINE OBSTRUCTION; LEUKOPENIA; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MALE; MULTIPLE CYCLE TREATMENT; NEUTROPENIA; PANCREAS FISTULA; PERITONEUM METASTASIS; POSTOPERATIVE COMPLICATION; POSTOPERATIVE HEMORRHAGE; PRIORITY JOURNAL; SIDE EFFECT; STOMACH CANCER; SURGICAL INFECTION; TREATMENT RESPONSE;

AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DRUG COMBINATIONS; FEMALE; FOLLOW-UP STUDIES; HUMANS; INJECTIONS, INTRAPERITONEAL; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; OXONIC ACID; PERITONEAL NEOPLASMS; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; STOMACH NEOPLASMS; SURVIVAL RATE; TAXOIDS; TEGAFUR; TREATMENT OUTCOME;

EID: 83455172626     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.22057     Document Type: Article

References (33)

1. Ferlay J, Shin HR, Bray F, et al.: Estimates of worldwide burden of cancer in 2008. Int J Cancer 2010; 127: 2893-2917.
2. Parkin DM, Bray F, Ferlay J, et al.: Global cancer statistics, 2002. CA Cancer J Clin 2005; 55: 74-108. (Pubitemid 40372904)
3. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 2001; 345: 725-730.
4. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for respectable gastroesophageal cancer. N Engl J Med 2006; 355: 11-20.
5. Ajani JA, Fairweather J, Dumas P, et al.: Phase II study of Taxol in patients with advanced gastric carcinoma. Cancer J Sci Am 1988; 4: 269-274.
6. Einzig AI, Neuberg D, Remick SC, et al.: Phase II trial of docetaxel (Taxotere) in patients with adenocarcinoma of the upper gastrointestinal tract previously untreated with cytotoxic chemotherapy: The Eastern Cooperative Oncology Group (ECOG) results of protocol E1293. Med Oncol 1996; 13: 87-93. (Pubitemid 27019943)
7. Futatsuki K, Wakui A, Nakao I, et al.: Late phase II study of irinotecan hydrochloride (CPT-11) in advanced gastric cancer. CPT-11 Gastrointestinal Cancer Study Group. Jpn J Cancer Chemother 1994; 21: 1033-1038. (Pubitemid 24225031)
8. Taguchi T, Tsukagoshi S, Furue H, et al.: Phase I clinical study of oxaliplatin. Jpn J Cancer Chemother 1998; 25: 1899-1907.
9. Sakata Y, Ohtsu A, Horikoshi N, et al.: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1(1M tegafur-0.4M Gimestat-1M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 1998; 34: 1715-1720. (Pubitemid 28474225)
10. Liu C, Sun Q, Hang X, et al.: Multicenter phase II study of capecitabine plus oxaliplatin as a first-line therapy in Chinese patients with advanced gastric cancer. Anticancer Drugs 2008; 19: 825-831.
11. Maruyama K, Kaminishi M, Hayashi K, et al.: Gastric cancer treated in 1991 in Japan: Data analysis of nationwide registry. Japanese Gastric Cancer Association Registration Committee. Gastric Cancer 2006; 9: 51-66. (Pubitemid 43890701)
12. Shirao K, Boku N, Yamada Y, et al.: Randomized phase III study of 5-Fluorouracil continuous infusion (5FUci) versus methotrexate and 5-FU sequential therapy (MF) in gastric cancer with peritoneal metastasis (JCOG0106). J Clin Oncol 2009; 27: 17.
13. Van Cutsem E, Moiseyenko VM, Tjulandin S, et al.: V325 Study Group Phase III study of docetaxel and cisplatin plus fluorouracil compared with cisplatin and fluorouracil as first-line therapy for advanced gastric cancer: A report of the V325 Study Group. J Clin Oncol 2006; 24: 4991-4997. (Pubitemid 46631401)
14. Webb A, Cunningham D, Scarffe JH, et al.: Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer. J Clin Oncol 1997; 15: 261-267. (Pubitemid 27020582)
15. Koizumi W, Narahara H, Hara T, et al.: S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol 2008; 9: 215-221.
16. Sakuramoto S, Sasako M, Yamaguchi T, et al.: ACTS-GC Group. Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 2007; 357: 1810-1820. (Pubitemid 350044801)
17. Mori T, Fujiwara Y, Yano M, et al.: Prevention of peritoneal metastasis of human gastric cancer cells in nude mice by S-1, a novel oral derivative of 5-fluorouracil. Oncology 2003; 64: 176-182. (Pubitemid 36173384)
18. Ishizone S, Maruta F, Saito H, et al.: Efficacy of S-1 for patients with peritoneal metastasis of gastric cancer. Chemotherapy 2006; 52: 301-307. (Pubitemid 44608668)
19. Morgan RJ Jr, Doroshow JH, Synold T, et al.: Phase I trial of intraperitoneal docetaxel in the treatment of advanced malignancies primarily confined to the peritoneal cavity: Dose-limiting toxicity and pharmacokinetics. Clin Cancer Res 2003; 9: 5896-5901. (Pubitemid 38018073)
20. Yoshida K, Ninomiya M, Takakura N, et al.: Phase II study of docetaxel and S-1 combination therapy for advanced or recurrent gastric cancer. Clin Cancer Res 2006; 12: 3402-3407.
21. Yamaguchi K, Shimamura T, Hyodo I, et al.: Phase I/II study of docetaxel and S-1 in patients with advanced gastric cancer. Br J Cancer 2006; 94: 1803-1808. (Pubitemid 43884569)
22. Fujiwara Y, Nishida T, Takiguchi S, et al.: Feasibility study of S-1 and intraperitoneal docetaxel combination chemotherapy for gastric cancer with peritoneal dissemination. Anticancer Res 2010; 30: 1335-1339.
23. Makino T, Fujiwara Y, Takiguchi S, et al.: The utility of pre-operative peritoneal lavage examination in serosa-invading gastric cancer patients. Surgery 2010; 148: 96-102.
24. Therasse P, Arbuck SG, Eisenhauer EA, et al.: New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 2000; 92: 205-216. (Pubitemid 30099779)
25. Fushida S, Kinoshita J, Yagi Y, et al.: Dual anti-cancer effects of weekly intraperitoneal docetaxel in treatment of advanced gastric cancer patients with peritoneal carcinomatosis: A feasibility and pharmacokinetic study. Oncol Rep 2008; 19: 27.
26. Yoshikawa T, Sasako M, Yamamoto S, et al.: Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg 2009; 96: 1015-1022.
27. Okabe H, Ueda S, Obama K, et al.: Induction chemotherapy with S-1 plus cisplatin followed by surgery for treatment of gastric cancer with peritoneal dissemination. Ann Surg Oncol 2009; 16: 3227-3236.
28. Fujiwara Y, Takiguchi S, Nakajima K, et al.: Neoadjuvant intra-peritoneal and systemic chemotherapy (NIPS) for gastric cancer patients with peritoneal dissemination. Ann Surg Oncol 2011; May 17. [Epub ahead of print] PMID: 21584835.
29. Fujii M, Kim YH, Satoh T, et al.: Randomized phase III study of S-1 alone versus S-1 plus docetaxel (DOC) in the treatment for advanced gastric cancer (AGC): The START trial update, J Clin Oncol 2011 29: (suppl; abstr 4016) This is an Abstract for ASCO 2011.
30. Markman M, Bundy BN, Alberts DS, et al.: Phase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: An intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology Group. J Clin Oncol 2001; 19: 1001-1007. (Pubitemid 32176274)
31. Armstrong DK, Bundy B, Wenzel L, et al.: Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N Engl J Med 2006; 354: 34-43. (Pubitemid 43048949)
32. Ishigami H, Kitayama J, Kaisaki S, et al.: Phase II study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 2010; 21: 67-70.
33. Japanese Gastric Cancer Association. Japanese classification of gastric carcinoma-2nd english edition. Gastric Cancer 1998; 1: 10-24.